26 related articles for article (PubMed ID: 10216507)
1. CTpathway: a CrossTalk-based pathway enrichment analysis method for cancer research.
Liu H; Yuan M; Mitra R; Zhou X; Long M; Lei W; Zhou S; Huang YE; Hou F; Eischen CM; Jiang W
Genome Med; 2022 Oct; 14(1):118. PubMed ID: 36229842
[TBL] [Abstract][Full Text] [Related]
2. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.
Lipner MB; Peng XL; Jin C; Xu Y; Gao Y; East MP; Rashid NU; Moffitt RA; Herrera Loeza SG; Morrison AB; Golitz BT; Vaziri C; Graves LM; Johnson GL; Yeh JJ
JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32213714
[TBL] [Abstract][Full Text] [Related]
3. Divergent roles of lysyl oxidase family members in ornithine decarboxylase- and RAS-transformed mouse fibroblasts and human melanoma cells.
Kielosto M; Eriksson J; Nummela P; Yin M; Hölttä E
Oncotarget; 2018 Dec; 9(102):37733-37752. PubMed ID: 30701028
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic adenocarcinoma protein-protein interaction network analysis.
Rezaei-Tavirani M; Rezaei-Tavirani S; Ahmadi N; Naderi N; Abdi S
Gastroenterol Hepatol Bed Bench; 2017; 10(Suppl1):S85-S92. PubMed ID: 29511477
[TBL] [Abstract][Full Text] [Related]
5. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer.
Joshi S; Cruz E; Rachagani S; Guha S; Brand RE; Ponnusamy MP; Kumar S; Batra SK
Mol Oncol; 2016 Aug; 10(7):1063-77. PubMed ID: 27185392
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer.
Stark JL; Mehla K; Chaika N; Acton TB; Xiao R; Singh PK; Montelione GT; Powers R
Biochemistry; 2014 Mar; 53(8):1360-72. PubMed ID: 24512202
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.
Takahashi R; Hirata Y; Sakitani K; Nakata W; Kinoshita H; Hayakawa Y; Nakagawa H; Sakamoto K; Hikiba Y; Ijichi H; Moses HL; Maeda S; Koike K
Cancer Sci; 2013 Mar; 104(3):337-44. PubMed ID: 23237571
[TBL] [Abstract][Full Text] [Related]
8. Emerging roles of ATF2 and the dynamic AP1 network in cancer.
Lopez-Bergami P; Lau E; Ronai Z
Nat Rev Cancer; 2010 Jan; 10(1):65-76. PubMed ID: 20029425
[TBL] [Abstract][Full Text] [Related]
9. Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism.
Shin S; Asano T; Yao Y; Zhang R; Claret FX; Korc M; Sabapathy K; Menter DG; Abbruzzese JL; Reddy SAG
Mol Cancer Res; 2009 May; 7(5):745-754. PubMed ID: 19435822
[TBL] [Abstract][Full Text] [Related]
10. Activation of oxidative stress-responsive signaling pathways in early splenotoxic response of aniline.
Wang J; Wang G; Ansari GA; Khan MF
Toxicol Appl Pharmacol; 2008 Jul; 230(2):227-34. PubMed ID: 18420242
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun.
Chen T; Hwang H; Rose ME; Nines RG; Stoner GD
Cancer Res; 2006 Mar; 66(5):2853-9. PubMed ID: 16510608
[TBL] [Abstract][Full Text] [Related]
12. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue.
Abe N; Watanabe T; Suzuki Y; Matsumoto N; Masaki T; Mori T; Sugiyama M; Chiappetta G; Fusco A; Atomi Y
Br J Cancer; 2003 Dec; 89(11):2104-9. PubMed ID: 14647145
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 oncogene antibodies differentiate between the normal and diseased pancreas, and between chronic pancreatitis and pancreatic cancer.
Standop J; Schneider M; Ulrich A; Mathiak G; Brand RE; Buechler MW; Pour PM
Oncol Rep; 2004 Dec; 12(6):1309-15. PubMed ID: 15547756
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study of c-jun protein expression on proliferation and apoptosis of laryngeal cancer cells].
Que YH; Ma XL
Ai Zheng; 2003 May; 22(5):500-3. PubMed ID: 12753711
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 and c-jun expression in pancreatic cancer: a prognostic marker?
Ferrara C; Tessari G; Poletti A; Giacon C; Meggiato T; Martines D; Del Favero G; Naccarato R
Oncol Rep; 1999; 6(5):1117-22. PubMed ID: 10425312
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localisation of the c-fos oncoprotein in pancreatic cancers.
Lee CS; Charalambous D
Zentralbl Pathol; 1994 Aug; 140(3):271-5. PubMed ID: 7947635
[TBL] [Abstract][Full Text] [Related]
17. Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue.
Nephew KP; Choi CM; Polek TC; McBride R; Bigsby RM; Khan SA; Husseinzadeh N
Gynecol Oncol; 2000 Mar; 76(3):388-96. PubMed ID: 10684716
[TBL] [Abstract][Full Text] [Related]
18. The expression of proto-oncogene c-jun in human pancreatic cancer.
Tessari G; Ferrara C; Poletti A; Dubrovich A; Corsini A; Del Favero G; Naccarato R
Anticancer Res; 1999; 19(1B):863-7. PubMed ID: 10216507
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
